Extensive partnering opportunities
exist in the prescription drug space
OUT-LICENSING of existing products
Our prodrug TAAP™ and MPAR™ technologies can be applied to most drugs, whether proprietary or generic. Our worldwide patent portfolio covers these technologies, with 45 issued patents globally, 30 pending and 17 issued US patents. Out-Licensing is an opportunity for non-US Opioid Abuse-Deterrent products & global ADHD Overdose Programs.
partner specific applications
As new drugs come to market that are shown to have addictive and/or abusive profiles, our technology can be applied to address those concerns while expanding a firm's product pipeline. The potential application of THC (Tetrahydrocannabinol) is a good example of a category of drugs that could benefit from TAAP™ and MPAR™.
Life Cycle Management / Revitalizing Drugs
As pharmaceutical companies look to extend their proprietary patent and market positioning with their highly scheduled assets, abuse-deterrence & overdose are variables that are addressable in a prodrug solution. The benefits of a novel Ensysce prodrug NCE (new chemical entity) solution are the obtainable patent real estate in otherwise commoditized markets, leading to an extended proprietary market position and various product derivatives.